Skip to main content
SpringerLink
Log in

Trials and therapies in secondary progressive MS, simplified

  • Comment
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

The FDA approvals of siponimod and cladribine for secondary progressive multiple sclerosis raise questions about the diagnostic criteria for multiple sclerosis phenotypes and their applicability to clinical trials. A simpler classification for the disease could be the answer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kappos, L. et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391, 1263–1273 (2018).

    Article  CAS  Google Scholar 

  2. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”. Ann. Neurol. 58, 840–846 (2005).

    Article  Google Scholar 

  3. Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162–173 (2018).

    Article  Google Scholar 

  4. Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014).

    Article  Google Scholar 

  5. Montalban, X. et al. Cladribine tablets added to IFN-beta in active relapsing MS: the ONWARD study. Neurol. Neuroimmunol. Neuroinflamm. 5, e477 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology and Neurotherapeutics, the University of Texas Southwestern Medical Center, Dallas, TX, USA

    Navid Manouchehri & Olaf Stüve

  2. Neurology Section, VA North Texas Health Care System, Medical Service Dallas, VA Medical Center, Dallas, TX, USA

    Olaf Stüve

Authors
  1. Navid Manouchehri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olaf Stüve
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olaf Stüve.

Ethics declarations

Competing interests

O.S. serves on the editorial board of Therapeutic Advances in Neurological Disorders, has served on data monitoring committees for Genentech–Roche, Pfizer and TG Therapeutics without monetary compensation, has advised Celgene, EMD Serono, Genzyme and Serono, and has received grant support from Sanofi Genzyme. N.M. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manouchehri, N., Stüve, O. Trials and therapies in secondary progressive MS, simplified. Nat Rev Neurol 15, 431–432 (2019). https://doi.org/10.1038/s41582-019-0233-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-019-0233-x

  • Springer Nature Limited

This article is cited by

Search

Navigation